半自动封闭玻璃化法与手动开放法在IVF中的随机对照研究
该研究为随机、多中心、开放、非劣效性试验,在三个德国IVF中心比较半自动封闭Gavi®与手动开放Cryotop®对2PN期卵母细胞玻璃化的效果。结果显示两组2PN存活率非劣效,胚胎发育和妊娠结局相似,但Gavi®操作时间更长且人员便利性更低。
要点
- Gavi®组2PN存活率94.0%,Cryotop®组96.7%,加权均数差-1.6%(95%CI -4.7至1.4),满足非劣效。
- 两组胚胎发育、优质胚胎比例、妊娠率和活产率相似。
- Gavi®组平均总操作时间更长(81±39分钟 vs 47±15分钟,均数差34分钟,95%CI 19至48),人员便利性更低。
核心结论
- 半自动封闭玻璃化法(Gavi®)的临床结果与手动开放法(Cryotop®)相似,达到非劣效,但操作时间更长且人员便利性更低。
研究设计与样本
- 前瞻性、随机、开放、非劣效性试验,在三个德国IVF中心开展(2017年10月至2018年12月)。
- 随机化按中心和玻璃化指征分层,随机患者149例,符合方案人群118例。
- 研究对象为18-40岁接受IVF或ICSI、有2PN卵母细胞可玻璃化的不育女性。
主要发现
- 2PN存活率:Gavi®组94.0%±13.5,Cryotop®组96.7%±9.7,加权均数差-1.6%(95%CI -4.7至1.4,P=0.28)。
- 两组胚胎发育、优质胚胎比例、妊娠率和活产率相似。
- 平均总操作时间(玻璃化+复温):Gavi®组81±39分钟,Cryotop®组47±15分钟,均数差34分钟(95%CI 19至48)。
- 由八名操作者问卷评估的人员便利性Gavi®系统更低,多数受访者因实用性问题偏好Cryotop®法。
关键数值与推荐
- 非劣效界值:2PN存活率均数差的95%CI下限排除大于9.5%的差异。
临床怎么用
- 在需要对操作标准化和组织安全有更高要求时,半自动封闭玻璃化法可作为手动开放法的合适替代技术。
- 选择Gavi®系统时需考虑操作时间延长和人员便利性降低对工作流程的影响。
局限性
- 研究在具有长期手动玻璃化经验的中心进行,在手动操作经验较少的机构中Gavi®的相对表现和人员便利性可能更高。
- 试验期间未测量两种操作的经济成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are outcome and procedural differences when using the semi-automated closed Gavi® device versus the manual open Cryotop® method for vitrification of pronuclear (2PN) stage oocytes within an IVF program? SUMMARY ANSWER: A semi-automated closed vitrification method gives similar clinical results as compared to an exclusively manual, open system but higher procedure duration and less staff convenience. WHAT IS KNOWN ALREADY: A semi-automated closed vitrification device has been introduced to the market, however, little evaluation of its performance in a clinical setting has been conducted so far. STUDY DESIGN, SIZE, DURATION: This prospective, randomised, open non-inferiority trial was conducted at three German IVF centers (10/2017-12/2018). Randomization was performed on day of fertilization check, stratified by center and by indication for vitrification (surplus 2PN oocytes in the context of a fresh embryo transfer (ET) cycle or 'freeze-all' of 2PN oocytes). PARTICIPANT/MATERIAL, SETTING, METHODS: The study population included subfertile women, aged 18-40 years, undergoing IVF or ICSI treatment after ovarian stimulation, with 2PN oocytes available for vitrification. The primary outcome was survival rate of 2PN oocytes at first warming procedure in a subsequent cycle and non-inferiority of 2PN survival was to be declared if the lower bound 95% CI of the mean difference in survival rate excluded a difference larger than 9.5%; secondary, descriptive outcomes included embryo development, pregnancy and live birth rate, procedure time and staff convenience. MAIN RESULTS AND THE ROLE OF CHANCE: The randomised patient population consisted of 149 patients, and the per-protocol population (patients with warming of 2PN oocytes for culture and planned ET) was 118 patients. The survival rate was 94.0% (±13.5) and 96.7% (±9.7) in the Gavi® and the Cryotop® group (weighted mean difference -1.6%, 95% CI -4.7 to 1.4, P = 0.28), respectively, indicating non-inferiority of the Gavi® vitrification/warming method for the primary outcome. Embryo development and the proportion of top-quality embryos was similar in the two groups, as were the pregnancy and live birth rate. Mean total procedure duration (vitrification and warming) was higher in the Gavi® group (81 ± 39 min vs 47 ± 15 min, mean difference 34 min, 95% CI 19 to 48). Staff convenience assessed by eight operators in a questionnaire was lower for the Gavi® system. The majority of respondents preferred the Cryotop® method because of practicality issues. LIMITATIONS, REASON FOR CAUTION: The study was performed in centers with long experience of manual vitrification, and the relative performance of the Gavi® system as well as the staff convenience may be higher in settings with less experience in the manual procedure. Financial costs of the two procedures were not measured along the trial. WIDER IMPLICATIONS OF THE FINDINGS: With increasing requirements for standardization of procedures and tissue safety, a semi-automated closed vitrification method may constitute a suitable alternative technology to the established manual open vitrification method given the equivalent clinical outcomes demonstrated herein. STUDY FUNDING/COMPETING INTERESTS: The trial received no direct financial funding. The Gavi® instrument, Gavi® consumables and staff training were provided for free by the distributor (Merck, Darmstadt, Germany) during the study period. The manufacturer of the Gavi® instrument had no influence on study protocol, study conduct, data analysis, data interpretation or manuscript writing. J.H. has received honoraria and/or non-financial support from Ferring, Merck and Origio. G.G. has received honoraria and/or non-financial support from Abbott, Ferring, Finox, Gedeon Richter, Guerbet, Merck, MSD, ObsEva, PregLem, ReprodWissen GmbH and Theramex. The remaining authors have no competing interests. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT03287479. TRIAL REGISTRATION DATE: 19 September 2017. DATE OF FIRST PATIENT’S ENROLMENT: 10 October 2017.
引用
- Hajek J, Baron R, Sandi-Monroy N, et al. A randomised, multi-center, open trial comparing a semi-automated closed vitrification system with a manual open system in women undergoing IVF. Hum Reprod. 2021. PMID: 34131726. doi:10.1093/humrep/deab140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。